Vaxcyte publishes positive VAX-31 phase 1/2 data in Lancet study

March 18, 2026 7:34 PM

Vaxcyte Inc. (NASDAQ: PCVX) announced the publication of results from its VAX-31 adult phase 1/2 clinical study in The Lancet ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found